ERIC P TAMM to Combined Modality Therapy
This is a "connection" page, showing publications ERIC P TAMM has written about Combined Modality Therapy.
Connection Strength
0.105
-
Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging. 2006 Sep-Oct; 31(5):568-74.
Score: 0.029
-
Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.
Score: 0.018
-
A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2018 12 01; 24(23):5883-5894.
Score: 0.017
-
Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010 Jul; 17(7):1794-801.
Score: 0.010
-
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3487-95.
Score: 0.009
-
Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery. 2007 Dec; 142(6):867-75; discussion 867-75.
Score: 0.008
-
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006 Aug; 13(8):1035-46.
Score: 0.007
-
Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 2005 Jun; 28(3):227-33.
Score: 0.007